Literature DB >> 30223039

Lost medicines: a longer view of the pharmaceutical industry with the potential to reinvigorate discovery.

Michael S Kinch1, Grant A Kinch2, Rebekah H Griesenauer2.   

Abstract

It is widely understood that the 1962 Kefauver-Harris Amendment to the Food, Drug and Cosmetics Act ushered in the modern regulation of medicines requiring a combination of safety and efficacy. However, fewer appreciate the amendment was applied retroactively to virtually all medicines sold in the USA. For various reasons, many medicines faded into history. Here, we identify and analyze >1600 medicines (including over-the-counter drugs) and their innovators prior to the enactment of Kefauver-Harris. We report 880 of these past medicines are no longer accessible. This project also reveals new insight into the pharmaceutical enterprise, which reveals an industry already mature and beginning to retract before enactment of the legislation. Beyond its historical implications, the recollection of these medicines could offer potential starting points for the future development of much-needed drugs.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30223039      PMCID: PMC7245331          DOI: 10.1016/j.drudis.2018.09.006

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  8 in total

Review 1.  Diagnosing the decline in pharmaceutical R&D efficiency.

Authors:  Jack W Scannell; Alex Blanckley; Helen Boldon; Brian Warrington
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

2.  Approval and withdrawal of new antibiotics and other antiinfectives in the U.S., 1980-2009.

Authors:  Kevin Outterson; John H Powers; Enrique Seoane-Vazquez; Rosa Rodriguez-Monguio; Aaron S Kesselheim
Journal:  J Law Med Ethics       Date:  2013       Impact factor: 1.718

Review 3.  Lessons from 60 years of pharmaceutical innovation.

Authors:  Bernard Munos
Journal:  Nat Rev Drug Discov       Date:  2009-12       Impact factor: 84.694

Review 4.  Innovator Organizations in New Drug Development: Assessing the Sustainability of the Biopharmaceutical Industry.

Authors:  Michael S Kinch; Ryan Moore
Journal:  Cell Chem Biol       Date:  2016-06-23       Impact factor: 8.116

Review 5.  An overview of FDA-approved vaccines & their innovators.

Authors:  Rebekah H Griesenauer; Michael S Kinch
Journal:  Expert Rev Vaccines       Date:  2017-09-25       Impact factor: 5.217

6.  Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act.

Authors:  P M Wax
Journal:  Ann Intern Med       Date:  1995-03-15       Impact factor: 25.391

Review 7.  An overview of FDA-approved new molecular entities: 1827-2013.

Authors:  Michael S Kinch; Austin Haynesworth; Sarah L Kinch; Denton Hoyer
Journal:  Drug Discov Today       Date:  2014-03-26       Impact factor: 8.369

Review 8.  Phage therapy--constraints and possibilities.

Authors:  Anders S Nilsson
Journal:  Ups J Med Sci       Date:  2014-03-30       Impact factor: 2.384

  8 in total
  1 in total

Review 1.  Paving New Roads Towards Biodiversity-Based Drug Development in Brazil: Lessons from the Past and Future Perspectives.

Authors:  Fernão Castro Braga
Journal:  Rev Bras Farmacogn       Date:  2021-09-17       Impact factor: 2.010

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.